What Chai Discovery Announced About the Novartis Antibody Collaboration

Chai Discovery announced on 13 July 2026 that Novartis will get access to its AI models, including Chai-3, to support therapeutic antibody discovery across multiple targets. Financial terms were not disclosed, and the announcement gives no number of programs or milestones. Fiona Marshall, Novartis's president of biomedical research, is quoted saying AI is already reshaping how the company discovers medicines and that applying advanced models to problems like antibody design lets it explore a broader range. Joshua Meier, Chai's co-founder and chief executive, is quoted calling it a significant step forward. The announcement also names Pfizer and Eli Lilly as earlier users of Chai's models.

Why the Chai Discovery Novartis Collaboration Matters to Biologics Teams

This is an access agreement, which is the lightest kind of deal in this field. A large drug company can hand a model to a research group, try it on a few targets and walk away without ever announcing that it stopped. Nothing here is a result, and nothing here involves a patient. What it does tell a biologics team is that the design models cleared whatever internal review Novartis runs before outside software touches real programs, and that Chai now has three of the largest drug companies on that list. Treat the names as a signal about the software being taken seriously, not as evidence that it works.

Where the Chai Discovery Update Comes From

Chai Discovery is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Chai Discovery original source.

How We Would Research the Chai Discovery Novartis Collaboration

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would start by asking Novartis biomedical research which targets or disease areas the models are being used on, because an access agreement that names no program can mean anything from one pilot to company-wide use.
  2. Then we would read Novartis's own media releases and pipeline updates for any antibody program that credits an AI design step, which is the first public sign the work went past evaluation.
  3. We would also check whether the later GSK and Bristol Myers Squibb announcements describe deeper commitments than this one, since the order these deals were signed in shows how Chai's terms are changing.